Merck & Co Inc (NYSE:MRK) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $60.1, down by -0.6%, with a volume of 8,039,016 shares against an average volume for the last 3 months of 11,301,000.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Merck & Co Inc (NYSE:MRK) is currently trading 5.53% below its 52-week-high, 14.5% above its 52-week-low. The 1-year range for the stock is $52.49 – $63.62. Merck & Co Inc (MRK) has a price to earnings ratio of 15.61 versus Healthcare sector average of 38.68. MRK stock price has outperformed the S&P 500 by 3.1%. The Medical Drugs company is currently valued at $169.8 billion and its share price closed the last trading session at $60.1. The stock has a 50-day moving average of $58.79 and a 200-day moving average of $59.13.
Merck & Co Inc (MRK) current short interest stands at 29.53 million shares. It has decreased by 8% from the same period of last month. Around 2% of the company’s shares, which are float, are short sold. With a 10-days average volume of 8.09 million shares, the number of days required to cover the short positions stand at 3.7 days.
MRK reported last quarter earnings on April 28. The Medical Drugs company announced earnings per share of $0.85 against a consensus Street estimate of $0.75, beating the average estimate by $0.1. This corresponds to a decrease of $0.14 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently nineteen analysts that cover MRK stock. Of those nineteen, seven have a Buy rating, twelve have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $65.94.
A recent analyst activity consisted of Jefferies reiterating their Hold stance on May 21. Jefferies increased their price target on MRK from $63 to $66. This corresponds to a 9.82% upside from the last closing price. On the date of report, the stock closed at $60.1.
Leerink Swann reiterated their Market Perform stance on March 16, and decreased their price target from $66 to $62.5. This corresponds to a 3.99% upside from the last closing price. On the date of report, the stock closed at $57.12.
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.